Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer

Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Nature medicine (Impact Factor: 27.36). 12/2012; 19(1). DOI: 10.1038/nm.3029
Source: PubMed


Inactivation of the von Hippel-Lindau tumor suppressor gene, VHL, is an archetypical tumor-initiating event in clear cell renal carcinoma (ccRCC) that leads to the activation of hypoxia-inducible transcription factors (HIFs). However, VHL mutation status in ccRCC is not correlated with clinical outcome. Here we show that during ccRCC progression, cancer cells exploit diverse epigenetic alterations to empower a branch of the VHL-HIF pathway for metastasis, and the strength of this activation is associated with poor clinical outcome. By analyzing metastatic subpopulations of VHL-deficient ccRCC cells, we discovered an epigenetically altered VHL-HIF response that is specific to metastatic ccRCC. Focusing on the two most prominent pro-metastatic VHL-HIF target genes, we show that loss of Polycomb repressive complex 2 (PRC2)-dependent histone H3 Lys27 trimethylation (H3K27me3) activates HIF-driven chemokine (C-X-C motif) receptor 4 (CXCR4) expression in support of chemotactic cell invasion, whereas loss of DNA methylation enables HIF-driven cytohesin 1 interacting protein (CYTIP) expression to protect cancer cells from death cytokine signals. Thus, metastasis in ccRCC is based on an epigenetically expanded output of the tumor-initiating pathway.

Download full-text


Available from: Joseph Michael Scandura,
  • Source
    • "A significant aspect of VHL mutation is that it does not automatically drive ccRCC into metastasis or correlate with poor clinical outcome, but rather it is the CXCR4 expression that contributes to poor prognosis (Vanharanta et al., 2013). Recent studies demonstrate that genes beneficial for tumor cell survival and metastasis, such as CXCR4 and CYTIP, are selected for and induced through selective epigenetic changes in polycomb repression complex 2 (PRC2), eventually driving the metastatic phenotype of a subpopulation of VHL-mutated ccRCCs (Vanharanta et al., 2013). In essence, CXCR4 expression is an important prognostic factor in ccRCCs (Li et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chemokines mediate numerous physiological and pathological processes related primarily to cell homing and migration. The chemokine CXCL12, also known as stromal cell-derived factor-1, binds the G-protein-coupled receptor CXCR4, which, through multiple divergent pathways, leads to chemotaxis, enhanced intracellular calcium, cell adhesion, survival, proliferation, and gene transcription. CXCR4, initially discovered for its involvement in HIV entry and leukocytes trafficking, is overexpressed in more than 23 human cancers. Cancer cell CXCR4 overexpression contributes to tumor growth, invasion, angiogenesis, metastasis, relapse, and therapeutic resistance. CXCR4 antagonism has been shown to disrupt tumor-stromal interactions, sensitize cancer cells to cytotoxic drugs, and reduce tumor growth and metastatic burden. As such, CXCR4 is a target not only for therapeutic intervention but also for noninvasive monitoring of disease progression and therapeutic guidance. This review provides a comprehensive overview of the biological involvement of CXCR4 in human cancers, the current status of CXCR4-based therapeutic approaches, as well as recent advances in noninvasive imaging of CXCR4 expression.
    Advances in Cancer Research 10/2014; 124:31-82. DOI:10.1016/B978-0-12-411638-2.00002-1 · 5.32 Impact Factor
  • Source
    • "The previous studies demonstrated that CXCR4 was mediated by the hypoxia-inducible transcription factor (HIF) pathway and had a critical role in tumour initiation and metastasis in patients with RCC (Staller et al, 2003; Vanharanta et al, 2013). A recent paper reported that galectin-1 could promote tumour progression through upregulation of CXCR4 via NF-kB in RCC (Huang et al, 2014). "
    H An · L Xu · Y Zhu · T Lv · W Liu · Y Liu · H Liu · L Chen · J Xu · Z Lin ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Aberrant CXC chemokine receptor 4 (CXCR4) expressions in malignant tissues have been reported; however, its role in kidney cancer prognosis remains unknown. The aim of this study was to determine the prognostic value of CXCR4 expression in patients with clear-cell renal cell carcinoma (ccRCC). Methods: The study included 225 patients with ccRCC. The cohort was split into a training set (n=125) and a validation set (n=100). CXC chemokine receptor 4 expression was analysed by immunohistochemical staining and its correlations with clinicopathologic features and prognosis were evaluated. Results: CXCR4-staining intensity increased gradually accompanied with disease progression from TNM stages I to IV in 225 patients with ccRCC. Moreover, high CXCR4 expression indicated reduced overall survival (OS) in the training (P<0.001) and validation (P<0.001) sets, especially for patients with early-stage (TNM stage I+II) diseases. Furthermore, CXCR4 expression was identified as an independent prognostic factor for OS, and combining TNM stage with CXCR4 expression showed a better prognostic value for OS in both sets. Conclusions: High CXCR4 expression, an independent adverse prognostic factor, could be combined with TNM stage to generate a predictive nomogram for clinical outcome in patients with ccRCC.
    British Journal of Cancer 04/2014; 110(9). DOI:10.1038/bjc.2014.179 · 4.84 Impact Factor
  • Source
    • "Review in primary tumors is reflected in metastasis signatures that predict relapse to various organs in clinical tumor cohorts (Bos et al., 2009; Cheung et al., 2013; Minn et al., 2005; Nguyen et al., 2009b; Padua et al., 2008; Tavazoie et al., 2008; Valastyan et al., 2009; Vanharanta et al., 2013; Zhang et al., 2009). These findings have provided important insights into the biology of metastatic dissemination and the proteins and microRNAs mediating it. "
    [Show abstract] [Hide abstract]
    ABSTRACT: How cancer cells acquire the competence to colonize distant organs remains a central question in cancer biology. Tumors can release large numbers of cancer cells into the circulation, but only a small proportion of these cells survive on infiltrating distant organs and even fewer form clinically meaningful metastases. During the past decade, many predictive gene signatures and specific mediators of metastasis have been identified, yet how cancer cells acquire these traits has remained obscure. Recent experimental work and high-resolution sequencing of human tissues have started to reveal the molecular and tumor evolutionary principles that underlie the emergence of metastatic traits.
    Cancer cell 10/2013; 24(4):410-21. DOI:10.1016/j.ccr.2013.09.007 · 23.52 Impact Factor
Show more